Marshall Wace’s enGene Therapeutics ENGN Stock Holding History

Marshall Wace’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.34M	Hold	343,928	–	–	﹤0.01%	1697
2025 Q4	$3.11M	Hold	343,928	–	–	﹤0.01%	1372
2025 Q3	$2.35M	Hold	343,928	–	–	﹤0.01%	1535
2025 Q2	$1.25M	Sell	343,928 -1,469	-0.4%	-$5.51K	﹤0.01%	1763
2025 Q1	$1.55M	Sell	345,397 -248,345	-42%	-$1.54M	﹤0.01%	1584
2024 Q4	$3.95M	Sell	593,742 -87,803	-13%	-$682K	﹤0.01%	1169
2024 Q3	$4.5M	Sell	681,545 -83,100	-11%	-$618K	0.01%	1036
2024 Q2	$7.21M	Sell	764,645 -35,355	-4%	-$454K	0.01%	861
2024 Q1	$13.6M	Buy	+800,000	New	+$9.79M	0.02%	643

Other funds holding ENGN

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Marshall Wace's ENGN Position: Q1 2026 in Review

Marshall Wace held its enGene Therapeutics (ENGN) position steady in Q1 2026 at 343,928 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #1697.

Marshall Wace first reported a position in ENGN in Q1 2024 and has held it in 9 quarters since. The position peaked at $13.6M in Q1 2024. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

Marshall Wace held 343,928 shares of enGene Therapeutics worth $2.34M as of Q1 2026.
Marshall Wace left its enGene Therapeutics share count unchanged in Q1 2026.
enGene Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1697 holding.
Marshall Wace first reported a position in enGene Therapeutics in Q1 2024 and has held it in 9 quarters since.
Marshall Wace's enGene Therapeutics position peaked at $13.6M in Q1 2024.
61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.